COMMUNIQUÉS West-GlobeNewswire

Valneva participera à différentes conférences d’investisseurs aux États-Unis et en Europe au cours du mois de juin
26/05/2025
Saint-Herblain (France), le 26 mai 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui que des membres de son équipe dirigeante effectueront des présentations [...]
Valneva to Participate at U.S. and European Investor Conferences in June
26/05/2025
Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming [...]
Transactions under Novonesis’ share buyback program
26/05/2025
Please read the announcement in PDF Attachment 2025_26_Share_buyback_program
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
26/05/2025
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids [...]
Australia Delivers Certainty for US Biotechs in 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, and R&D Rebates
26/05/2025
ADELAIDE, Australia, May 26, 2025 (GLOBE NEWSWIRE) -- As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase [...]
Transactions in Connection with Share Buy-back Program
26/05/2025
Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital [...]
Brain Cancer Canada Awards $85K to Cutting-Edge Recurrent Glioblastoma Research
26/05/2025
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $85,000 research grant awarded to Dr. Stéphane Angers at the University of Toronto for his project, "Discovery of Druggable [...]
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
26/05/2025
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
VIRBAC: Communiqué précisant les modalités de mise à disposition ou de consultation des documents préparatoires à l’assemblée générale mixte ordinaire et extraordinaire
26/05/2025
Les actionnaires de la société VIRBAC sont avisés qu’une assemblée générale mixte ordinaire et extraordinaire se tiendra le jeudi 19 juin 2025 à 9 heures , dans les bâtiments de VIRBAC direction, 13 e rue LID 06517 [...]
Maple Report: Over Half of Canadian Women Say the Health Care System Fails to Meet Their Needs
26/05/2025
A national survey of over 1,500 women reveals care delays, misdiagnoses and dismissed concerns are widespread, signaling broader system strain and the need for earlier, more proactive care. TORONTO, May 26, 2025 (GLOBE [...]
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
26/05/2025
TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of [...]
Guerbet : Changes in the composition of the Guerbet board of directors.
26/05/2025
CHANGES IN THE COMPOSITION OF THE GUERBET BOARD OF DIRECTORS Reorganization of the Board of Directors Directors' terms of office reduced to 4 years Appointment of Ms Michèle Lesieur and Mr Eric Drapé as independent [...]
Guerbet : Evolution de la composition du Conseil d'administration de Guerbet.
26/05/2025
EVOLUTION DE LA COMPOSITION DU CONSEIL D’ADMINISTRATION DE GUERBET ___________________________________________________________________________ Recomposition du Conseil d’administration Réduction de la durée des mandats [...]
ICPO Forum 2025: Advancing Theranostics in Precision Oncology
26/05/2025
Over 220 experts from around the globe came together to shape the future of radiotheranostics for better cancer patient outcomes Wiesbaden – May 26, 2025 — The International Centers for Precision Oncology (ICPO) [...]
Chair of Sernova Biotherapeutics Resigns
26/05/2025
LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid [...]
SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
25/05/2025
– S’il est approuvé, le mirdamétinib devrait être le premier et unique traitement dans l’Union européenne à bénéficier d’une autorisation de mise sur le marché pour les adultes et les enfants atteints de NF1-PN – – La [...]
ZLNA – Issuance of shares through set-off of option exercise fee
24/05/2025
Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on 29 April 2025 to grant the Company's Board of Directors an authorisation to issue new shares, each [...]
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent une réelle efficacité et une bonne durabilité dans le traitement de 1re ligne contre le CETC r/m PD-L1+
24/05/2025
- Taux de réponse de 63 % observé chez les 43 patients évaluables - Taux de survie général de 79 % au bout de 12 mois ; survie sans progression de niveau moyen à 9 mois - Conférence téléphonique le jeudi 22 mai à 17 h [...]
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
24/05/2025
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – [...]

Pages